Physician profile
Muhammad Shoaib
NPI 1619540622
$778.53
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $747 · Education: $31.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.55 |
| Education | $31.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $87.61 | 2024 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $84.95 | 2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $78.77 | 2024 | Lupkynis |
| Amgen INC. | $75.43 | 2024 | Tavneos |
| Calliditas Therapeutics US INC. | $64.08 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.46 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $54.87 | 2024 | |
| Ardelyx, INC. | $42.40 | 2024 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $38.30 | 2024 | Terlivaz |
| Lilly USA, LLC | $36.94 | 2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $31.98 | 2024 | Rayaldee |
| Genzyme Corporation | $26.39 | 2024 | |
| Alnylam Pharmaceuticals INC. | $23.77 | 2024 | Onpattro |
| Daiichi Sankyo INC. | $22.07 | 2024 | Injectafer |
| Chiesi USA, INC. | $21.98 | 2024 | Elfabrio |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $18.99 | 2024 | Defencath |
| Bayer Healthcare Pharmaceuticals INC. | $13.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Shoaib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.